The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Expands manufacturing push & locks in major growth deals
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
U.S. business drives strong growth as Lupin reports 57% rise in Q4 U.S. sales and 43% increase in gross profit
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Hair care & quick commerce shine
With robust FY26 growth, plans AI-led diagnostics and genomic testing expansion
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The standout story remains Wegovy, particularly its new oral formulation
FY26 revenue rises 17% to Rs. 5,453 crore as US generics business jumps 49% and adjusted EBITDA margin improves to 26% for the quarter
Subscribe To Our Newsletter & Stay Updated
